Last reviewed · How we verify

HPA, ANS stimulation

University of Texas at Austin · FDA-approved active Small molecule ✓ Verified May 2026

HPA, ANS stimulation is a Small molecule drug developed by University of Texas at Austin. It is currently FDA-approved. Also known as: vivarin, cortef.

HPA stimulation activates the hypothalamic-pituitary-adrenal axis to enhance sympathetic nervous system activity and stress hormone release.

Researchers have studied the effects of HPA and ANS stimulation on anxiety through clinical trials, comparing these interventions to a placebo. The HPA and ANS systems are protein-based, as indicated by their modality classification in ChEMBL.

At a glance

Generic nameHPA, ANS stimulation
Also known asvivarin, cortef
SponsorUniversity of Texas at Austin
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

The hypothalamic-pituitary-adrenal (HPA) axis is a central neuroendocrine system that regulates stress responses through release of corticotropin-releasing hormone, adrenocorticotropic hormone, and cortisol. Stimulation of this axis via ANS (autonomic nervous system) activation increases sympathetic tone and glucocorticoid secretion, which can modulate immune function, metabolism, and cardiovascular responses. This mechanism may be leveraged therapeutically in conditions where enhanced stress hormone signaling or sympathetic activation is beneficial.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HPA, ANS stimulation

What is HPA, ANS stimulation?

HPA, ANS stimulation is a Small molecule drug developed by University of Texas at Austin.

How does HPA, ANS stimulation work?

HPA stimulation activates the hypothalamic-pituitary-adrenal axis to enhance sympathetic nervous system activity and stress hormone release.

Who makes HPA, ANS stimulation?

HPA, ANS stimulation is developed and marketed by University of Texas at Austin (see full University of Texas at Austin pipeline at /company/university-of-texas-at-austin).

Is HPA, ANS stimulation also known as anything else?

HPA, ANS stimulation is also known as vivarin, cortef.

What development phase is HPA, ANS stimulation in?

HPA, ANS stimulation is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing